Elicio Therapeutics, Inc. — Director's Dealing 2021

Dec 29, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Angion Biomedica Corp. (ANGN)
CIK: 0001601485
Period of Report: 2021-12-27

Reporting Person: Venkatesan Jay (Director, See Remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-27	Common Stock	P	66907	$2.5486	Acquired	1428920	Direct
2021-12-28	Common Stock	P	210337	$2.6617	Acquired	1639257	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.54 to $2.55 inclusive.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.55 to $2.75 inclusive.